1. Home
  2. TBPH vs INDI Comparison

TBPH vs INDI Comparison

Compare TBPH & INDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • INDI
  • Stock Information
  • Founded
  • TBPH 2013
  • INDI 2007
  • Country
  • TBPH United States
  • INDI United States
  • Employees
  • TBPH N/A
  • INDI N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • INDI Semiconductors
  • Sector
  • TBPH Health Care
  • INDI Technology
  • Exchange
  • TBPH Nasdaq
  • INDI Nasdaq
  • Market Cap
  • TBPH 699.0M
  • INDI 790.2M
  • IPO Year
  • TBPH N/A
  • INDI N/A
  • Fundamental
  • Price
  • TBPH $14.58
  • INDI $4.38
  • Analyst Decision
  • TBPH Strong Buy
  • INDI Strong Buy
  • Analyst Count
  • TBPH 4
  • INDI 5
  • Target Price
  • TBPH $23.00
  • INDI $5.90
  • AVG Volume (30 Days)
  • TBPH 367.5K
  • INDI 4.2M
  • Earning Date
  • TBPH 11-11-2025
  • INDI 11-06-2025
  • Dividend Yield
  • TBPH N/A
  • INDI N/A
  • EPS Growth
  • TBPH N/A
  • INDI N/A
  • EPS
  • TBPH 0.26
  • INDI N/A
  • Revenue
  • TBPH $77,205,000.00
  • INDI $217,685,000.00
  • Revenue This Year
  • TBPH $79.82
  • INDI $4.53
  • Revenue Next Year
  • TBPH N/A
  • INDI $31.60
  • P/E Ratio
  • TBPH $56.32
  • INDI N/A
  • Revenue Growth
  • TBPH 24.49
  • INDI N/A
  • 52 Week Low
  • TBPH $7.88
  • INDI $1.53
  • 52 Week High
  • TBPH $15.15
  • INDI $5.57
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 60.51
  • INDI 60.62
  • Support Level
  • TBPH $14.00
  • INDI $3.88
  • Resistance Level
  • TBPH $14.87
  • INDI $4.17
  • Average True Range (ATR)
  • TBPH 0.50
  • INDI 0.23
  • MACD
  • TBPH -0.02
  • INDI 0.06
  • Stochastic Oscillator
  • TBPH 62.00
  • INDI 84.78

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About INDI indie Semiconductor Inc.

Indie Semiconductor Inc is empowering the Autotech revolution with next-generation automotive semiconductors and software platforms. It focuses on edge sensors for Driver Assistance Systems including LiDAR, connected car, user experience, and electrification applications. These technologies represent the core underpinnings of both electric and autonomous vehicles, while the user interfaces transform the in-cabin experience to mirror and seamlessly connect to the mobile platforms. Geographically, the company generates majority of its revenue from Greater China and rest from United States, Europe, South Korea and other regions.

Share on Social Networks: